<< Back

Hartford Hospital Named Radiopharmaceutical Therapy Center of Excellence

July 18, 2024

Hartford Hospital has been named a Society of Nuclear Medicine and Molecular Imaging Designated Radiopharmaceutical Therapy Center of Excellence, becoming the first in Connecticut and second in New England to receive the honor.

The designation recognizes Hartford Hospital for meeting rigorous standards in patient care, training and expertise in radiopharmaceutical therapy. The focus of the designation is the innovative field of theranostics, which uses targeted radiation for both imaging and treating cancer.

Hartford Hospital launched its Theranostics Program in 2018 with the FDA approval of Lutathera™, used to treat advanced neuroendocrine cancer. In 2022, the FDA approved Pluvicto™ to treat advanced prostate cancer, and Hartford Hospital was the first to use it in Connecticut. Patients throughout Connecticut, New England, and New York have been referred for evaluation and treatment to Hartford Hospital’s Theranostics Program.

“We are pleased to receive this national level of recognition for excellence in radiopharmaceutical therapy, and proud to be the first in Connecticut to achieve the designation,” said Andrew Salner, MD, medical director of the Hartford HealthCare Cancer Institute at Hartford Hospital. “This honor is a testament to the collaborative efforts of our entire team from radiation oncology, nuclear medicine, radiation safety, oncology nursing, and oncology pharmacy. We believe there is great potential for new agents that could target various types of cancer in the future, offering hope to the patients we are privileged to care for.”